Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles

Definitions

• the present invention relates to a drug compound antirheumatic and analgesic indication.
• phenyl butazone (1,2-diphenyl- 3,5-dioxo-4-n-butyl-pyrazolidine) has analgesic and antirheumatic effects.
• phenyl butazone was considered to be the most effective antirheumatic drug, apart from the steroids.
• the administration of phenyl butazone in effective dosages is accompanied by serious side effects, caused by its inhibiting action on certain enzymatic reactions taking place in the body.
• the objective underlying the present invention was therefore the discovery of a drug based on phenyl butazone which retains the known antirheumatic effects of phenyl butazone, while having a strong analgesic indication at reduced dosage, so that the known side effects are eliminated, or at least reduced.
• mice In a series of writhing tests performed on mice it was found that especially favorable results are obtained with a drug compound in which dextro-propoxyphene and phenyl butazone are present in a molar ratio of l to 2. These results are reflected in a table given below in which some of the readings obtained in the tests are listed by way of example. The effectiveness of the different drug compounds is stated as a percentage in relation to the l to 2 molar ratio.
• the extraordinary analgesic effects achieved are particularly evident in the category of post-traumatic conditions.
• the treatment results obtained in other typical categories of the rheumatoid group indicates that the antirheumatic effects of phenyl butazone in the disclosed combination fully match previously observed effects of treatment with phenyl butazone in its known large dosage, even though its dosage in the disclosed combination is substantially reduced.
• Drug composition having an antirheumatic and analgesic indication containing as active ingredients dextropropoxyphene and phenyl butazone in moleratio between 1 to l and l to 8.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=5843353

Family Applications (1)

Country Status (12)

Citations (2)

• 1972
  • 1972-04-26 DE DE2220500A patent/DE2220500C3/de not_active Expired
• 1973
  • 1973-04-24 FR FR7316250*A patent/FR2182249B1/fr not_active Expired
  • 1973-04-25 GB GB1952573A patent/GB1431661A/en not_active Expired
  • 1973-04-26 US US354558A patent/US3890444A/en not_active Expired - Lifetime
  • 1973-04-26 BE BE130448A patent/BE798758A/xx unknown
  • 1973-04-26 AT AT373873A patent/AT331967B/de not_active IP Right Cessation
  • 1973-04-26 CA CA170,092A patent/CA1014473A/en not_active Expired
  • 1973-04-26 NL NL7305850.A patent/NL160487C/xx not_active IP Right Cessation
  • 1973-04-26 DD DD170455A patent/DD102916A1/xx unknown
  • 1973-04-26 ZA ZA732847A patent/ZA732847B/xx unknown
  • 1973-04-26 LU LU67498A patent/LU67498A1/xx unknown
  • 1973-05-01 AU AU55048/73A patent/AU5504873A/en not_active Expired

Patent Citations (2)

Also Published As

Similar Documents